Ckd-504 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 8 | Huntington disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03713892 (ClinicalTrials.gov) | May 23, 2018 | 17/10/2018 | CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects | Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, PK, PD of CKD-504 in Single SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects | Huntington Disease | Drug: CKD-504;Drug: Placebo | Chong Kun Dang Pharmaceutical | NULL | Recruiting | 19 Years | 45 Years | All | 88 | Phase 1 | Korea, Republic of |